AstraZeneca (AZN) says Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV NSCLC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. MU
4. DPZ
5. ACN
6. NAVN
7. DFTX
8. IBM
9. META
10. ENRD

Go back to AstraZeneca (AZN) says Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV NSCLC
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 12,511